Good
Mostly Aligned
Patient Risk:
Low
Summary
The provided evaluated claim is supported by the supplied label text (embryo-fetal development study in monkeys). However, the overall set of user claims was not evaluated against the label text, so only limited alignment can be confirmed.
Category Scores
Accurate Statements
COSENTYX use during pregnancy is associated with no observed adverse developmental effects in infants from pregnant monkeys after secukinumab administration during organogenesis.
Supported by label 8.1 Pregnancy - Risk Summary: 'In an embryo-fetal development study, no adverse developmental effects were observed in infants born to pregnant monkeys after subcutaneous administration of secukinumab during organogenesis at doses up to 30 times the MRHD.'
Unsupported Statements
Contradictions
Important Omissions
The evaluation dataset includes multiple other pregnancy-related claims (e.g., placental crossing, newborn immune suppression, human data limitations, vaccine timing, half-life, fertility, patents/exclusivity, biosimilars), but those statements were not evaluated against the provided label excerpts. As a result, the report cannot confirm alignment for those claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only explicitly evaluated claim is limited to nonclinical monkey embryo-fetal development findings and does not introduce dosing or clinical management recommendations. Other claims were not assessed against the supplied label content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Only one label-supported pregnancy claim is assessed; other provided claims were not evaluated against the supplied label excerpts.
Suggested Improvement
Evaluate each provided claim directly against the corresponding sections of the supplied prescribing information (e.g., Pregnancy risk summary, PK elimination half-life, drug interactions, live vaccine guidance, and any immunogenicity/infant effects language if present).